Jan 12 (Reuters) - Revvity said on Monday it expects its 2025 adjusted profit per share to exceed its forecast of $4.90 to $5, as the medical equipment maker benefits from renewed demand for contract research and diagnostics services.
The company's shares were up nearly 6% in extended trading.
Pharmaceutical companies have ramped up drug development in the U.S. amid evolving trade policies under President Donald Trump.
Revvity said it expects to report fourth-quarter revenue of around $772 million, above Wall Street estimates of $760.3 million, according to data compiled by LSEG.
It also expects annual revenue to grow 4% to $2.86 billion, above estimates of $2.84 billion.
The company will report its fourth-quarter and full year 2025 results on February 2.
(Reporting by Puyaan Singh in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
The Best Games Crossroads in History - 2I served on the expert committee that advised the government on new dietary guidelines – most of our recommendations were ignored
- 3Astronomers may have spotted the 1st known 'superkilonova' double star explosion
- 4Foreign journalist kidnapped in Iraq: Interior Ministry
- 5What to know about voluntary chocolate recall
- Inflammatory Merz remarks on migrants' violence against women slammed
- The most effective method to Alter Your Kona SUV for Greatest Solace and Comfort
- Faulty glucose monitors linked to 7 deaths and more than 700 injuries, FDA warns
- Get away from the Tedious Drudgery: Go into Business Today!
- Vote in favor of your #1 Sort of Convenience for a Family
- Tracking down the Right Equilibrium: Charges versus Personal Costs in Senior Protection.
- HGV driver recruited others to smuggle migrants
- Big majority in Germany call Berlin's efforts on gas prices too weak
- $1,000 bribes, Mormon momfluencer mixers and making content to get plastic surgery: The wildest things I learned reporting my book
